Therefore, to further evaluate the potential consequences of IL-6 resistance in type 2 diabetes, we assessed AMPK activity in response to 30 and 60 minutes of exposure to recombinant IL-6 in He myocytes and DM myocytes (Table 2). The gene discussed is PRKAA2; the disease is type 2 diabetes mellitus.